Litigation

Recent Posts

U.S. High Court Won’t Hear Arguments That Punitives Are Preempted In Drug Cases
Posted on 7 Oct 2013 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) The U.S. Supreme Court on Oct. 7 refused to hear arguments by Novartis Pharmaceuticals Corp. that federal drug regulations and high court precedent preempt the awarding of state law punitive damages in an Aredia... Read More

N.J. Jury Finds For Defendant Novartis In Zometa Jaw Injury Trial
Posted on 16 May 2013 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A New Jersey state court jury on May 15 returned a defense verdict for Novartis Pharmaceuticals Corp. in a Zometa jaw injury case, a source told Mealey Publications ( Beverly Meng v. Novartis Pharmaceuticals Corp.... Read More

High Court Refuses To Address If Zometa Class Action Tolled Statute of Limitations
Posted on 31 May 2011 by Tom Moylan

WASHINGTON ,D.C. - (Mealey's) On May 31, the U.S. Supreme Court declined Novartis Pharmaceuticals Corp.'s request to decide if a pending Zometa federal court class action tolls the statute of limitations on an individual state court action that... Read More

$12.8M Verdict For Jaw Injury In Aredia/Zometa Case To Be Reduced To $1.14M
Posted on 24 Nov 2010 by Tom Moylan

WINSTON-SALEM, N.C. - (Mealey's) A North Carolina federal jury on Nov. 22 awarded $12,887,001 in an Aredia/Zometa jaw injury case, a verdict that will be reduced to $1,148,001 by North Carolina's limit on punitive damages ( Herbert Fussman, et... Read More

N.J. Jury Finds Novartis Didn't Fail To Warn About Jaw Risk From Aredia, Zometa Bone Drugs
Posted on 7 Oct 2010 by Tom Moylan

NEW BRUNSWICK, N.J. -- A New Jersey state court jury on Oct. 6 found that Novartis Pharmaceuticals Corp. did not fail to provide adequate warning to a cancer patient's doctor that its bone-saving drugs Aredia and Zometa had a risk of osteonecrosis... Read More

Jury Awards $1.3 Million In Zometa Jaw Injury Trial After Botching 1st Verdict Form
Posted on 23 Sep 2013 by Tom Moylan

ORLANDO, Fla. — (Mealey’s) A Florida federal jury on Sept. 20 found that Novartis Pharmaceuticals Corp. failed to warn a cancer patient about the risk of osteonecrosis of the jaw (ONJ) and awarded her $1.3 million in medical expenses and non... Read More

Jury Awards Plaintiff $10.4 Million For Injuries, Punitive Damages Linked To Novartis' Zometa
Posted on 5 Nov 2012 by Tom Moylan

CENTRAL ISLIP, N.Y. - (Mealey's) A New York federal jury on Nov. 2 found Novartis Pharmaceuticals Corp. liable for a woman's osteonecrosis of the jaw (ONJ) and awarded her $10.45 million, according to the parties ( Barbara Davids v. Novartis Pharmaceuticals... Read More

Novartis Wins Defense Verdict In Zometa Jaw Injury Trial
Posted on 26 May 2011 by Tom Moylan

BROOKLYN, N.Y. (Mealey's) A New York federal jury in the first federal Zometa trial found May 25 that the plaintiff did not prove by a preponderance of evidence that the Novartis Pharmaceuticals Corp. drug caused a decedent's osteonecrosis of... Read More

Tennessee Federal Judge Won’t Dismiss Jaw Injury Cases
Posted on 9 Mar 2010 by LexisNexis Litigation Resource Community Staff

NASHVILLE, Tenn. – (AP) A federal judge in Nashville has refused to dismiss 40 lawsuits against a Swedish-based pharmaceutical company accused of failing to warn patients that two of its drugs can cause severe deterioration of the jaw. U.S... Read More